Vaxcyte sets October 5 readout for pivotal VAX-31 vaccine trial
Vaxcyte will present topline results from the pivotal OPUS-1 Phase 3 trial of its VAX-31 pneumococcal vaccine candidate on October 5. The event creates a binary clinical readout for the company’s lead late-stage program, with safety, tolerability and immunogenicity central to the update.
The story
Vaxcyte said it will host a webcast and conference call on October 5 at 8:00 a.m. ET to present topline data from OPUS-1, a pivotal adult Phase 3 trial of VAX-31. The study is evaluating the 31-valent pneumococcal conjugate vaccine candidate for safety, tolerability and immunogenicity in the prevention of invasive pneumococcal disease and pneumococcal pneumonia.
The announcement schedules the readout rather than reporting the trial results themselves. OPUS-1 is an adult pivotal study, making the presentation an important next data point for Vaxcyte’s clinical-stage vaccine platform and its lead candidate.
The results will touch Vaxcyte’s development program directly: the safety and tolerability findings will address the candidate’s clinical profile, while immunogenicity will provide the key evidence on its vaccine response. The company’s stated target is protection against invasive pneumococcal disease and pneumococcal pneumonia.
No topline findings were included in the announcement. The October 5 presentation should establish the reported safety profile and immunogenicity results, along with the company’s next stated development steps.
Our read · Sun, Oct 4
Vaxcyte will present topline OPUS-1 Phase 3 results for its 31-valent VAX-31 vaccine on October 5.
Why. The next trading decision turns on the safety and immunogenicity profile Vaxcyte reports for its pivotal adult study, not on the scheduling announcement itself. The October 5 readout is the concrete catalyst; without the results, the clinical and commercial implications remain unresolved.
Both cases
What could change this view: The readout could show safety, tolerability or immunogenicity results that fail to support the VAX-31 development plan, or the presentation could leave key efficacy and regulatory questions unresolved.
Who reported it · 2
Keep reading
More on PCVX
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior NotesLatest on the Wire
Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →Latest on the Wire
Anthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by GlobeNewswire as Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
, . Who answers for this
2 reports from 1 publisher in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →